Natpar

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
22-12-2023

Ingredient activ:

parathyroid hormone

Disponibil de la:

Takeda Pharmaceuticals International AG Ireland Branch

Codul ATC:

H05AA03

INN (nume internaţional):

parathyroid hormone

Grupul Terapeutică:

Calcium homeostasis

Zonă Terapeutică:

Hypoparathyroidism

Indicații terapeutice:

Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.

Rezumat produs:

Revision: 16

Statutul autorizaţiei:

Authorised

Data de autorizare:

2017-04-24

Prospect

                                26
B. PACKAGE LEAFLET
27
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
NATPAR 25 MICROGRAMS/DOSE POWDER AND SOLVENT FOR SOLUTION FOR
INJECTION
NATPAR 50 MICROGRAMS/DOSE POWDER AND SOLVENT FOR SOLUTION FOR
INJECTION
NATPAR 75 MICROGRAMS/DOSE POWDER AND SOLVENT FOR SOLUTION FOR
INJECTION
NATPAR 100 MICROGRAMS/DOSE POWDER AND SOLVENT FOR SOLUTION FOR
INJECTION
Parathyroid hormone
This medicine is subject to additional monitoring. This will allow
quick identification of new
safety information. You can help by reporting any side effects you may
get. See the end of section 4
for how to report side effects.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Natpar is and what it is used for
2.
What you need to know before you use Natpar
3.
How to use Natpar
4.
Possible side effects
5.
How to store Natpar
6.
Contents of the pack and other information
7.
Instructions for use
1.
WHAT NATPAR IS AND WHAT IT IS USED FOR
WHAT IS NATPAR?
Natpar is a hormone replacement for adults with under-active
parathyroid glands, a condition known
as ‘hypoparathyroidism’.
Hypoparathyroidism is a disease caused by low levels of parathyroid
hormone, which is produced by
the parathyroid glands in the neck. This hormone controls the amount
of calcium and phosphate in the
blood and urine.
If your levels of parathyroid hormone are too low, you can have low
blood calcium. Low calcium can
cause symptoms in many parts of your body, including the bones, heart,
skin, muscles, kidneys, brain
and nerves. For a list of symptoms of low ca
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
This medicinal product is subject to additional monitoring. This will
allow quick identification of
new safety information. Healthcare professionals are asked to report
any suspected adverse reactions.
See section 4.8 for how to report adverse reactions.
1.
NAME OF THE MEDICINAL PRODUCT
Natpar 25 micrograms/dose powder and solvent for solution for
injection
Natpar 50 micrograms/dose powder and solvent for solution for
injection
Natpar 75 micrograms/dose powder and solvent for solution for
injection
Natpar 100 micrograms/dose powder and solvent for solution for
injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Natpar 25 micrograms
Each dose contains 25 micrograms parathyroid hormone (rDNA)* in 71.4
microlitre solution
following reconstitution.
Each cartridge contains 350 micrograms parathyroid hormone (rDNA).
Natpar 50 micrograms
Each dose contains 50 micrograms parathyroid hormone (rDNA) in 71.4
microlitre solution following
reconstitution.
Each cartridge contains 700 micrograms parathyroid hormone (rDNA).
Natpar 75 micrograms
Each dose contains 75 micrograms parathyroid hormone (rDNA) in 71.4
microlitre solution following
reconstitution.
Each cartridge contains 1050 micrograms parathyroid hormone (rDNA).
Natpar 100 micrograms
Each dose contains 100 micrograms parathyroid hormone (rDNA) in 71.4
microlitre solution
following reconstitution.
Each cartridge contains 1400 micrograms parathyroid hormone (rDNA).
*Parathyroid hormone (rDNA), produced in _E. coli_ using recombinant
DNA technology, is identical to
the 84 amino acid sequence of endogenous human parathyroid hormone.
Excipient(s) with known effect
Each dose contains 0.32 mg of sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
The powder is white and the solvent is a clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Natpar is indicated as adjunctive treatment of adult patients with
chronic hypoparathyro
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 22-12-2023
Raport public de evaluare Raport public de evaluare bulgară 26-04-2017
Prospect Prospect spaniolă 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 22-12-2023
Raport public de evaluare Raport public de evaluare spaniolă 26-04-2017
Prospect Prospect cehă 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 22-12-2023
Raport public de evaluare Raport public de evaluare cehă 26-04-2017
Prospect Prospect daneză 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 22-12-2023
Raport public de evaluare Raport public de evaluare daneză 26-04-2017
Prospect Prospect germană 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului germană 22-12-2023
Raport public de evaluare Raport public de evaluare germană 26-04-2017
Prospect Prospect estoniană 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 22-12-2023
Raport public de evaluare Raport public de evaluare estoniană 26-04-2017
Prospect Prospect greacă 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 22-12-2023
Raport public de evaluare Raport public de evaluare greacă 26-04-2017
Prospect Prospect franceză 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 22-12-2023
Raport public de evaluare Raport public de evaluare franceză 26-04-2017
Prospect Prospect italiană 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 22-12-2023
Raport public de evaluare Raport public de evaluare italiană 26-04-2017
Prospect Prospect letonă 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 22-12-2023
Raport public de evaluare Raport public de evaluare letonă 26-04-2017
Prospect Prospect lituaniană 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 22-12-2023
Raport public de evaluare Raport public de evaluare lituaniană 26-04-2017
Prospect Prospect maghiară 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 22-12-2023
Raport public de evaluare Raport public de evaluare maghiară 26-04-2017
Prospect Prospect malteză 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 22-12-2023
Raport public de evaluare Raport public de evaluare malteză 26-04-2017
Prospect Prospect olandeză 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 22-12-2023
Raport public de evaluare Raport public de evaluare olandeză 26-04-2017
Prospect Prospect poloneză 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 22-12-2023
Raport public de evaluare Raport public de evaluare poloneză 26-04-2017
Prospect Prospect portugheză 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 22-12-2023
Raport public de evaluare Raport public de evaluare portugheză 26-04-2017
Prospect Prospect română 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului română 22-12-2023
Raport public de evaluare Raport public de evaluare română 26-04-2017
Prospect Prospect slovacă 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 22-12-2023
Raport public de evaluare Raport public de evaluare slovacă 26-04-2017
Prospect Prospect slovenă 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 22-12-2023
Raport public de evaluare Raport public de evaluare slovenă 26-04-2017
Prospect Prospect finlandeză 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 22-12-2023
Raport public de evaluare Raport public de evaluare finlandeză 26-04-2017
Prospect Prospect suedeză 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 22-12-2023
Raport public de evaluare Raport public de evaluare suedeză 26-04-2017
Prospect Prospect norvegiană 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 22-12-2023
Prospect Prospect islandeză 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 22-12-2023
Prospect Prospect croată 22-12-2023
Caracteristicilor produsului Caracteristicilor produsului croată 22-12-2023
Raport public de evaluare Raport public de evaluare croată 26-04-2017

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor